Clinical Trial Search

Primary: Number of Adverse Events Within 1 Year (365 Days) That Are Related to AST-OPC1 Injection — 92; 122; 133; 118 Adverse Events

Primary: Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15 — 0.32; 0.56; 0.48; 0.35 g/L

Primary: Evaluate the Vascular Supply of the Bowel Intra-operatively and Correlate This With Postoperative Complications Identified During Their Hospital Stay at One Week and One…

Primary: Pain Intensity on Movement From 0-48 Hours Post-Treatment — 5.55; 5.87 score on a scale — p=0.124

Primary: Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group — -20.121 score on a scale

Primary: Is the Acquire Needle Non-inferior Compared to SharkCore Needle in Histologic Yield of the Sample Obtained? — 3; 4; 10; 14 Lesions

Primary: FcεRI (High Affinity Receptor) Levels at 3 Months — 20.5; 13.66 Positive cells per field

Primary: Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) — -3.66; -0.51; -4.00; -3.89 Seconds

Primary: Change in Overall Lip Fullness Grading Scale — 1.52; 1.53 score on a scale

Primary: Efficacy of IV Ibuprofen in Orthropedic Trauma Patients — 74.9; 97.8 morphine equivalent dosage, mg

Primary: Percent Area of Treatment Sites Requiring Autografting by Month 3 — 4.33; 102.10 percentage of treatment sites — p=<0.0001

Primary: Number of Retrieved Lymph Nodes Per Participant — 44.6; 41.5; 49.2; 39.2 lymph nodes

Primary: Incidence of Adverse Events as Assessed by CTCAE v4.0. — 3; 4; 4; 5 Participants

Primary: Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group — 14.9; 7.3 Months

Primary: Number of Participants Who Experienced One or More Adverse Events (AEs): — 27; 28; 31; 21 Participants